Finally, the authors performed in vitro aggregation and differential HDX-MS experiments to assess the effects of the drug candidate tramiprosate and the endogenous brain metabolite 3-sulfopropanoic acid on ApoE aggregation, both of which have demonstrated positive outcomes in AD patients with the APOE∗ε4 genotype (205). Here, APOE is linked to Alzheimer disease.